Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

EMGALITY DIN 02505134

Status: Marketed
Holder: ELI LILLY CANADA INC
Molecule: GALCANEZUMAB
Available to quote

Health Canada record

Active ingredient(s)GALCANEZUMAB 100 MG
Dosage formSolution
RouteSubcutaneous
ScheduleSCHEDULE D; PRESCRIPTION
ClassHuman
ATCN02CD02 GALCANEZUMAB
Original market date11-Jan-2021
Current status date11-Jan-2021
SourceHealth Canada DPD

Establishment licence of the holder

Eli Lilly Canada Inc. — licence 100164, currently licensed, last inspection rating C (2026-03-24).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing GALCANEZUMAB

DINProductCompanyFormStrengthStatus
02491060EMGALITYELI LILLY CANADA INCSolutionGALCANEZUMAB 120 MGMarketed
02491087EMGALITYELI LILLY CANADA INCSolutionGALCANEZUMAB 120 MGMarketed

Notices of Compliance

NOCDateSubmissionReason
242992020-09-17Supplement to a New Drug Submission (SNDS)ADDITIONAL PRESENTATION AND INDICATION: EMGALITY IS INDICATED FOR THE REDUCTION IN THE FREQUENCY OF ATTACKS THROUGHOUIT A CLUSTER PERIOD IN ADULTS WITH EPISODIC CLUSTER HEADACHE WITH PRIOR CLUSTER HEADACHE PERIODS LASTING AT LEAST 6 WEEKS AND WHO HAVE HAD AN INADEQUATE RESPONSE TO, OR TOLERATED POORLY, OF WHO HAD CONTRAINDICATIONS TO CONVENTIONAL PREVENTIVE THERAPIES ESTABLISHED Y CANADIAN PRACTICE GUIDELINES
Request a quote for EMGALITY

How to read a Canadian DIN record